Swedbank AB Increases Stock Position in Kenvue Inc. (NYSE:KVUE)

Swedbank AB increased its position in Kenvue Inc. (NYSE:KVUE) by 13.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 890,980 shares of the company’s stock after buying an additional 103,117 shares during the quarter. Swedbank AB’s holdings in Kenvue were worth $19,022,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KVUE. Valicenti Advisory Services Inc. lifted its position in Kenvue by 1.6% during the fourth quarter. Valicenti Advisory Services Inc. now owns 108,455 shares of the company’s stock valued at $2,316,000 after buying an additional 1,752 shares in the last quarter. Perigon Wealth Management LLC raised its stake in shares of Kenvue by 19.8% in the 4th quarter. Perigon Wealth Management LLC now owns 19,249 shares of the company’s stock valued at $408,000 after acquiring an additional 3,187 shares during the period. Cornell Pochily Investment Advisors Inc. lifted its holdings in shares of Kenvue by 17.4% during the 4th quarter. Cornell Pochily Investment Advisors Inc. now owns 10,917 shares of the company’s stock valued at $233,000 after acquiring an additional 1,615 shares in the last quarter. Mount Yale Investment Advisors LLC boosted its position in Kenvue by 50.6% during the 4th quarter. Mount Yale Investment Advisors LLC now owns 34,599 shares of the company’s stock worth $739,000 after purchasing an additional 11,632 shares during the period. Finally, Novare Capital Management LLC increased its holdings in Kenvue by 6.2% in the 4th quarter. Novare Capital Management LLC now owns 491,970 shares of the company’s stock valued at $10,504,000 after purchasing an additional 28,616 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the subject of several analyst reports. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a report on Monday, January 6th. JPMorgan Chase & Co. lifted their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. UBS Group decreased their target price on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, January 16th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Kenvue has an average rating of “Hold” and an average target price of $23.08.

Kenvue Stock Performance

Shares of Kenvue stock opened at $21.29 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The firm’s 50-day simple moving average is $21.90 and its 200-day simple moving average is $21.87. The firm has a market cap of $40.82 billion, a PE ratio of 38.71, a price-to-earnings-growth ratio of 2.05 and a beta of 1.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.31 earnings per share. Equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.85%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.